Thanks for the update, Ratfink. It is reassuring to hear that...

Thanks for the update, Ratfink. It is reassuring to hear that responses were frank and detailed.

While another cap raising can't be ruled out, I think the company has performed very steadily in pursuing the generic strategy. There is always going to be a bit of risk around execution, but I have felt reasonable expectations are being met.

With the increased Thiotepa revenues and likely upcoming generic launches (3 expected in nine months), the building blocks look to be in place for a lift-off in 2017. Let's hope Mayne and ANI are sufficiently incentivised to get the sales volumes through on the new products, as that may then be key.